The International Collaboration on Cosmetics Safety opens a new chapter with the selection of its 2026 Board officers, strengthening its worldwide dedication to promoting animal‑free innovations in cosmetics safety science amid swift regulatory and scientific evolution.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS works at the nexus of science, policy, and collective action, uniting a broad array of stakeholders who pursue a shared mission: advancing the worldwide integration and recognition of animal-free safety science for cosmetics and their components. The appointment of the 2026 Board officers highlights the organization’s commitment to preserving a strategic trajectory while navigating an increasingly intricate global environment, where expectations surrounding ethical research, scientific robustness, and regulatory coherence are continually shifting.
Ongoing leadership stability and broad international representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Acting collectively, the officers make up a Board leadership team whose experience extends across multinational corporations, industry groups, and regulatory science, strengthening ICCS’ role as a neutral forum for cooperation rather than an advocate for any particular sector. This equilibrium underpins the organization’s credibility, especially as it works to shape regulatory perspectives and promote alignment on animal-free safety approaches.
Advancing animal-free science through collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment approaches, when fully refined and validated, are not only ethically sound but also offer superior scientific performance. Since its establishment in early 2023, ICCS has sought to show that non-animal methods can deliver dependable and meaningful data to safeguard both human health and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing engagement from regulators across the globe.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific framework and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to enhance clarity and uniformity in how animal-free safety assessment methods are applied. This guidance sought to close gaps between scientific progress and regulatory requirements, delivering a practical reference that stakeholders could use when generating or reviewing non-animal data.
In parallel, ICCS contributed to the creation of innovative methodologies aligned with next generation risk assessment (NGRA), an evolving framework that combines cutting-edge in vitro, in silico, and exposure-driven techniques. These methods are increasingly recognized as vital to contemporary toxicology, providing the possibility of more human-relevant insights while decreasing dependence on animal studies. ICCS’ work in this area underscores its dedication to promoting ethical progress as well as scientific rigor.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A pivotal moment for cosmetics safety regulation
The installation of the 2026 Board officers unfolds amid a period of substantial shifts in global cosmetics regulations, as numerous markets revisit long‑established testing protocols in light of public expectations, scientific progress, and emerging international policy directions, and within this evolving landscape, organizations such as ICCS remain essential in coordinating innovation with regulatory demands so that advancement stays both trustworthy and sustainable.
ICCS leadership has long stressed that advancing animal-free safety science cannot happen through fragmented initiatives; rather, it demands synchronized efforts involving industry, academia, regulators, and civil society. This approach is mirrored in the Board’s makeup, which unites leaders who grasp the technical, regulatory, and organizational aspects required to drive meaningful change.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair emphasized the importance of leveraging ICCS’ global, multi-stakeholder model to close the gap between innovation and regulation. This approach aims to ensure that advances in animal-free science are not confined to research settings but translated into practical tools that regulators can trust and apply consistently.
Strengthening foundations for long-term impact
As ICCS anticipates 2026 and the years ahead, the organization remains committed to strengthening its accomplishments while broadening its influence. The newly confirmed Board leadership is expected to serve a key role in defining priorities that balance scientific aspiration with practical execution. This involves pinpointing areas requiring further guidance or consensus, supporting the validation and dissemination of emerging methodologies, and encouraging international harmonization to minimize fragmentation in regulatory expectations.
Education continues to be a central pillar of ICCS’ strategy, with the organization striving to offer accessible, science‑grounded materials and spaces for dialogue that help clarify the principles of animal‑free safety science and support well‑informed choices. This effort becomes especially vital in a field where misunderstandings or uneven levels of expertise can hinder advancement, even when the science itself is robust.
The organization’s structure, bringing together leading cosmetics and ingredient manufacturers alongside trade groups, research associations, and animal protection organizations, uniquely positions it to confront these challenges. This broad mix of viewpoints helps keep discussions balanced, well‑rounded, and centered on common objectives rather than limited agendas.
Based in New York, ICCS remains active as a worldwide initiative, underscoring the global character of cosmetic innovation and regulatory oversight. As products and their ingredients circulate internationally, coordinated standards and mutual acknowledgment of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science across the globe.
In confirming its 2026 Board officers, ICCS conveys steadiness while signaling continued progress, with its leadership team offering consistent guidance after a year of tangible accomplishments and the seasoned insight required to steer the upcoming phase of transformation; as scientific advances accelerate and regulatory expectations shift, the organization’s function as a convening force and driving agent for animal-free cosmetics safety science is poised to gain even greater significance.
In the end, the importance of the 2026 Board elections stems not only from the members selected but also from what their leadership conveys: an ongoing dedication to cooperation, scientific rigor, and the responsible evolution of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn vision into enduring results, shaping the future of cosmetics safety in a manner that brings ethics, science, and global public confidence into alignment.
